MCM2 and breast carcinoma: High expression of MCM2 in clinical samples was reported with CSC marker-positive breast cancer cells, and the MCM2-targeted therapeutic strategy, together with Hph-1-gp70 treatment to induce DNA damage, were regarded as a potential therapy for the eradication of stem-like cells from breast cancer tissue [45].